Category: Programs & Events

These posts feature lifestyles, events, welfare programs, perks and assistance, governmental goals, etc.

‘Celebrate the Green’ with D&R Greenway Land Trust and Voices Chorale NJ

Post author By Editor
Post date February 17, 2024
No Comments on ‘Celebrate the Green’ with D&R Greenway Land Trust and Voices Chorale NJ

In celebration of D&R Greenway Land Trust’s work to preserve the green in our local communities – back by popular demand – Voices Chorale N.J. is bringing Irish music and dancing to a benefit for both organizations just in time for St. Patrick’s Day on Friday, March 15, from 6 to 9 p.m. at D&R Greenway’s Johnson Education Center, 1 Preservation Place, Princeton.

Guests enjoying an Irish dance with friends at the ‘Celebrate the Green’ event last March. — Photo by Mary M. Michaels

A rainbow encompasses the carriage barn at the Johnson Education Center.

The Parnell Irish Band will entertain with guitar, drums and fiddle, providing lots of Irish music with vocals to engage the crowd in group singing. Irish jokes and stories will add to the fun as well as a unique opportunity to kick up your heels and learn the art of Irish Country Dancing.

Guests are encouraged to wear green and experience a pub-style setting while enjoying beer, wine and a light pub supper. The festivities will include a Silent Auction of unique items to support Voices Chorale N.J. Weather permitting, guests will be invited to gather outside on the patio for an Irish singalong by the firepit.

Gathering around the fire pit last year for an Irish singalong. — Photo by Philip S. Getty

“It’s easy to be green at this special event! D&R Greenway’s protection of over 22,000 acres of land keeps 40 shades of green in our Garden State. I can’t think of anything more fitting than to celebrate that bounty with an Irish festival of singing and camaraderie!” says D&R Greenway President & CEO, Linda Mead. Only 75 seats are available. By the “luck ‘o the Irish” be among the first come, first served and reserve your party’s seats now.

Imagine yourself regaled by music and laughter throughout the evening, capped by a procession to a bluestone terrace where a firepit will light the night as you join in lyrical celebration. According to past participants, this will be a magical moment to remember.

Voices Board of Directors President and choir member Jane Read says “Voices is excited to continue our partnership with D&R Greenway with this event. We look forward to sharing our music and enjoying the evening with friends old and new.”

Voices Chorale NJ is a non-profit, member-run, auditioned chorus based in Hopewell, NJ, which includes singers from central New Jersey and southeastern Pennsylvania under the direction of Dr. David A. McConnell. The mission of Voices Chorale NJ is to bring outstanding music to the public, inspire audiences, and provide performance opportunities for singers and local musicians. Voices sponsors a Young Composers Project for children from ages 5 – 12. https://www.voiceschoralenj.org. Follow Voices on Facebook and Instagram.

D&R Greenway Land Trust is an accredited nonprofit that has reached a milestone of over 22,000 acres of land preserved throughout central New Jersey since 1989. By protecting land in perpetuity and creating public trails, it gives everyone the opportunity to enjoy the great outdoors. The Land Trust’s preserved farms and community gardens provide local organic food for residents of the region—including those most in need. Through strategic land conservation and stewardship, D&R Greenway combats climate change, protects birds and wildlife, and ensures clean drinking water for future generations. D&R Greenway’s mission is centered on connecting land with people from all walks of life.https://www.drgreenway.org; info@drgreenway.org. Follow the organization on Facebook and Instagram.

Tickets for this festive event and benefit are $65 per person. Space is limited. To reserve your seat, visithttps://www.drgreenway.org; or https://www.voiceschoralenj.org or call 609-924-4646.

Business Culture Lifestyle Local News Perspectives Programs & Events

Mobile Academy hosts successful panel discussion on generational diversity

Post author By Editor
Post date February 17, 2024
No Comments on Mobile Academy hosts successful panel discussion on generational diversity

TRENTON, N.J. — The African American Chamber of Commerce of New Jersey’s (AACCNJ) Mobile Academy showcased its commitment to fostering collaboration and understanding within the business community with a successful event on Jan. 23 at Middlesex College.

The evening, themed “Can We Talk: What Do You Really Know About Generational Diversity?” unfolded as a multifaceted experience, beginning with a dynamic networking segment and light refreshments.

The networking session provided a unique opportunity for attendees to not only exchange business cards but also to share experiences and insights. Entrepreneurs, executives, and professionals from various sectors engaged in conversations that transcended generational gaps, setting the stage for an enriching and inclusive panel discussion.

The Mobile Academy, known for its innovative approach to education and empowerment, curated a diverse panel of experts, each representing a different generation. Gene Bouie, a seasoned leader and Executive Director of AACCNJ’s Training and Development Institute, brought a wealth of experience as the Baby Boomer representative. Stacey Kavanagh, First Vice President and Market Manager at Provident Bank shared her insights as a representative of Generation X. Kyle Holder, Vice President at Optimus Partners, LLC, offered perspectives from the Millennial generation. Desiree Mitchell, a student at New York University, brought a fresh perspective as the Generation Z representative.

Dr. Kinna Perry, an accomplished scholar and Associate Dean at Rutgers Graduate School-Newark, delivered a keynote address that transcended the theoretical, offering practical insights into the day-to-day implications of generational diversity. Dr. Perry’s presentation explored how each generation’s unique values, communication styles, and attitudes toward work impact our daily lives, from the office to our interactions in society at large.

The heart of the evening unfolded with a moderated panel discussion with Perry expertly navigating the complexities and commonalities that define each generation. The audience actively participated in a robust Q&A session, providing a platform for direct engagement with the panelists.

This exchange facilitated a deeper understanding of the challenges and opportunities that arise when working across generational lines.

John E. Harmon Sr., IOM, Founder, President and CEO of AACCNJ, delivered closing remarks, expressing his gratitude for the engaged audience and reinforcing the organization’s commitment to promoting diversity, equity, and inclusion. Harmon highlighted the pivotal role events like “Can We Talk” play in fostering a more cohesive and supportive business community.

About the African American Chamber of Commerce of New Jersey

The AACCNJ performs an essential role in the economic viability of New Jersey. While providing a platform for New Jersey’s African American business leaders, to speak with a collective voice, the AACCNJ advocates and promotes economic diversity fostering a climate of business growth through major initiatives centering on education and public policy. The Chamber serves as a proactive advocacy group with a 501(c) 3 tax exemption, which is shared by the National Black Chamber of Commerce.

Culture Environment Government Lifestyle Local News Programs & Events Science Travel & Leisure

Mercer County Park Commission announces summer nature camps

Post author By Editor
Post date February 16, 2024
No Comments on Mercer County Park Commission announces summer nature camps

HAMILTON, N.J. — The Mercer County Park Commission hosts thrilling and educational summer nature camps for children ages 7 to 15 years.

With activities like fishing, trail exploration, and nature games, these camps are designed for children who love to explore nature or want to build their experiences in the great outdoors.

All camps are licensed with the State of New Jersey and are led by our full-time Naturalist Educators. Offered in three of our county parks, summer nature camps highlight the full scope of unique wildlife and outdoor experiences that Mercer County has to offer.

Aquatic Adventure Camp for Anglers

For campers ages 10 to 12 and will take place on Mercer Lake. Campers will on build their fishing skills by choosing the right bait, identifying fish, and finding habitats along the lake for the most success. Only offered from June 24 to June 28!

Aquatic Adventure Camp for Kayakers

Campers ages 13 to 15 will have exclusive access to explore plant and animal life along Mercer Lake’s shoreline, creeks, and hidden coves by kayak. Only offered from June 24 to June 28!

Baldpate Nature Camp

This camp is packed with hands-on nature explorations, hikes through the forest, and unstructured nature play. Activities are designed for campers to delve into topics such as birds, bugs, and butterflies and include age-appropriate activities for campers 7 to 9 years, and 10 to 12 years. Only offered July 8 to 12, and July 15 to 19.

Tulpehaking Nature Camp

This camp has campers explore the trails of the marshlands through the lens of the Lenape, who inhabited this region centuries ago and continue to view it as their homeland. Age-appropriate activities incorporating traditional Lenape Games and crafts are designed for campers 7 to 9 years, and 10 to 12 years. Only offered July 29 to Aug. 2, and Aug. 5 to 9.

Register now. Camps fill quickly. See How to Register below for more information on how to claim your child’s spot in camp.

How to register:

Registration and payment must be completed online at https://register.communitypass.net/mercer. Camps are filled on a first-come, first-served basis, and spots are limited. Only complete applications will be processed. Make sure you have the following information before registering: child’s medical information (including physician and health insurance information, emergency contact etc.), immunization record, and full payment.

Click here for our full Nature Camp brochure with program dates and details or call (609) 888-3218 ext. 205.

Business Culture Economics Education Government Lifestyle Local News News Now! Perspectives Politics Programs & Events

The AACCNJ hosts town hall meeting with over 200 in attendance — Topic: ‘The Fierce Urgency of Now’

Post author By Editor
Post date February 15, 2024
No Comments on The AACCNJ hosts town hall meeting with over 200 in attendance — Topic: ‘The Fierce Urgency of Now’

TRENTON, N.J. — The African American Chamber of Commerce of New Jersey (AACCNJ) hosted a town hall on Feb. 7 , from 3 to 6 p.m., with over two hundred in attendance at the Crowne Plaza Princeton, Conference Center in East Windsor, N.J.

The meeting was convened to provide an open forum for discussion and included a presentation on the State’s newly released Disparity Study, conducted by Mason Tillman Associates, LTD.

The Presentation was led by Dr. Denise Anderson, Founder & CEO, Denise Anderson & Associates (DA&A) LLC, and moderated by John E. Harmon, Sr., IOM, Founder, President & CEO, AACCNJ, and included a lengthy Q&A session with the audience, which consisted of AACCNJ members, and stakeholders, elected officials, representatives from the state government, and Chambers of Commerce.

The State’s commissioned study documented institutional discrimination to African American businesses in NJ. Dr. Denise Anderson received a positive response to her statement “Disparities need to be addressed between Blacks and Whites and within minority groups. We need specific solutions for different populations based on the data and their needs. Regardless of how we are classified – lumping us as “minority” does not make us monolithic.”

Dr. Anderson’s presentation was met with a standing ovation at the conclusion. Dr. Anderson also quoted Frederick Douglass and James Baldwin in her presentation, quotes that resonated with the audience.

“Each day the AACCNJ and its members continue to fight what Dr. King called the ‘soft bigotry of low expectations,’ and we prove time and time again, that when the opportunity presents itself, we are ready,” said John E. Harmon, Sr.

Harmon set forth a call to action to those in attendance, to reach out to their local and state elected officials to voice their concerns, and to let them know they were in attendance. CEO Harmon fielded more than two dozen questions during the audience Q& A segment.

“I knew that we invited the right person to make a presentation to our constituents on the Disparity Study, Dr. Anderson’s knowledge and analysis of the data was excellent and was presented in a straightforward manner to the audience,” said Gary Mann, AACCNJ, Chairman of the Board.

“Tuesday marks two weeks since the state released the long-promised disparity study — one that showed all minority groups, as well as females, have received nowhere near their “fair share” of state contracts, based on their population size and their ability to do the work.

The 221-page report, commissioned in 2020, was filled with stunning data, including this fact: Even though Black-owned companies in the state represent 9.19% of the available construction businesses, they received only 0.14% of the dollars on construction contracts valued over $65,000 to $5.71 million. (The report estimates this potentially cost these businesses $209 million).

More stunning: These numbers didn’t surprise anyone, including state officials.

Even more stunning: The state, after releasing this report, seemingly has done little to address the issue. No focus groups, roundtable discussions, executive orders or legislative proposals have been announced.

After years of saying it needed a study to be able to do something, the state has not made any public announcements on how it will address the findings.”¹

“The Study, as expected, revealed that African American businesses received little of the $ 18.5 billion the Murphy administration spent on contracts for construction, professional services and goods and services from 2015 to 2020,” said John E. Harmon, Sr.

“While expecting the worst, little did we know that the Study would document African Americans received less than one (1) percent of the $18.5 billion dollars the State awarded to contractors. African American businesses received a pittance despite the fact that we represent, 14 percent of the population, and over 10 percent of the businesses in New Jersey willing and able to contract with the State.”

“As we move forward, we ask the Governor and his administration to also hold a statewide meeting, to discuss the results of the disparity study,” said Harmon.

“The Administration needs to establish a race and gender-based program with minority and woman-owned business utilization goals to end the discriminatory practices in its award of contracts,” said Harmon. “Our mutual goal henceforth is to have a more equitable participation in every area of the public sector wherein economic opportunities exist.”

The AACCNJ has convened a Disparity Study Task Force Committee to work with the Murphy administration to outline our engagement plan with the state and develop a strategy to address disparities and underperformance among Blacks in New Jersey. The task force will be co-chaired by Dr. Denise Anderson, Denise Anderson and Associates and Ferlanda Nixon, Esq., Chief of Public Policy & External Affairs, AACCNJ. Committee Members include John E. Harmon, Sr., President CEO, AACCNJ, Gary Mann, Chairman of the Board, AACCNJ, Tammeisha Smith, Vice Chair of the Board, Stan Prater, Senior Advisor to AACCNJ President & CEO, Tanya Freeman, Esq, Chair of the Board, NY State Black Business Alliance (NYSBBA), Robert Johnson, Esq., Secretary, AACCNJ, Board of Directors, Marcus Dyer, CPA, Treasurer, AACCNJ, Board of Directors, Robert Warrington, Esq., AACCNJ Board of Directors, and Monique Nelson, Executive Chair, UWG.

¹ https://www.roi-nj.com/2024/02/06/diversity-inclusion/2-weeks-after-release-of-shocking-disparity-study-state-seemingly-has-done-little-to-address-issue/

About the African American Chamber of Commerce of New Jersey

The African American Chamber of Commerce of New Jersey (AACCNJ) performs an essential role in the economic viability of New Jersey. While providing a platform for New Jersey’s African American business leaders, to speak with a collective voice, the AACCNJ advocates and promotes economic diversity fostering a climate of business growth through major initiatives centering on education and public policy. The Chamber serves as a proactive advocacy group with a 501(c) 3 tax exemption, which is shared by the National Black Chamber of Commerce.

Culture Education Lifestyle Local News Perspectives Programs & Events

Mobile Academy to host Career and Resources Fair at Stockton University in March

Post author By Editor
Post date February 14, 2024
No Comments on Mobile Academy to host Career and Resources Fair at Stockton University in March

TRENTON, N.J. — The African American Chamber of Commerce of New Jersey’s (AACCNJ) Mobile Academy announces its first Career and Resources Fair of 2024 to take place on March 1, at Stockton University.

The Career and Resources Fair will be at the university in Galloway, N.J., at 10 a.m.to 1 p.m., and will offer a range of services to support individuals in their professional journeys.

Highlights include career coaching sessions aimed at guiding attendees through their career paths. Participants will have the opportunity to receive expert feedback on their resumes, enhancing their ability to stand out in the competitive job market.

In addition to resume assessments, the fair will feature essential insights on mastering the art of interviews through specialized interviewing tips. Attendees can take advantage of free onsite haircuts, ensuring they look and feel their best for potential employers. Professional headshots will also be available, adding a polished touch to print and online profiles.

Employer eager to connect with talented individuals will be in attendance, providing a unique networking opportunity for job seekers. This presents a chance for attendees to explore potential career paths, learn about job openings, and make valuable connections with employers actively seeking new talents.

Job seekers interested in attending the event can register here:

https://mms.aaccnj.com/members/evr/reg_event.php?orgcode=AANJ&evid=80655345

Interested employers can contact the Mobile Academy at:

mobileacademy@aaccnj.com

Business Culture Economics Education Lifestyle News Now! Perspectives Programs & Events Regulations & Security

Affinity Federal Credit Union celebrates its first class of Certified Wellbeing Coaches

Post author By Michelle Dryden
Post date February 12, 2024
No Comments on Affinity Federal Credit Union celebrates its first class of Certified Wellbeing Coaches

Coaches will support the wellbeing of Affinity members at each of its branches in NJ, NY and CT

BASKING RIDGE, N.J. — (BUSINESS WIRE) — Affinity Federal Credit Union (“Affinity”) proudly announces the graduation of its inaugural class of Certified Wellbeing Coaches. The program and its first graduates mark an important step in Affinity’s ongoing commitment to the financial wellbeing of its members.

The program’s 42 graduates represent various departments within Affinity. Each participant invested approximately 75 hours in training, learning about how to provide members with the best possible support in managing their personal finances and overcoming financial challenges. Course topics include credit, foreclosure, bankruptcy, taxes, insurance, identity theft, and the resources and tools available to support a member’s financial wellbeing. The program was inclusive of class attendance, presentations, homework, and tests.

“We are immensely proud to introduce our first class of Certified Wellbeing Coaches, who embody Affinity’s purpose of ‘people helping people’ within our communities,” said Kevin Brauer, CEO and President of Affinity Federal Credit Union. “By investing in the financial wellbeing of our members, we are not just helping them navigate financial challenges but are also empowering them to achieve their long-term goals. We look forward to the positive impact our Wellbeing Coaches will have on our members’ lives.”

Affinity also wants to highlight the work of four of its coaches who went above and beyond to meet the demands of the program. Top graduates of the inaugural class of Certified Wellbeing Coaches include Bedminster and Morristown Branch Manager Andrea Alfaro, Norwalk Branch Manager Juan Londono, Financial Services Accountant Lizandra Blanco, and Loss Mitigation Specialist Auria Torres.

Coaches are now available at all of Affinity’s branches in New Jersey, New York, and Connecticut, ensuring that every member has access to this invaluable resource. Appointments with Wellbeing Coaches can be made online at https://www.affinityfcu.com/financial-wellbeing/certified-wellbeing-coaches.

About Affinity Federal Credit Union

Affinity Federal Credit Union is a full-service financial institution, member-owned and community-focused, with a mission to nurture your financial wellbeing. With more than 20 branches across the tri-state area, Affinity is the largest credit union headquartered in the state of New Jersey, proudly ranking in the top 2% of all credit unions in terms of asset size¹. The Affinity difference is about people helping people on a deeper level and understanding what YOU need to make your unique dreams a reality. For more information, please visit www.affinityfcu.com.

¹ Source: NCUA.gov. Using the “Credit Union and Corporate Call Report Data” found here: https://www.ncua.gov/analysis/credit-union-corporate-call-report-data

Contacts

Rocco Aloe

Gregory FCA for Affinity Federal Credit Union

affinity@gregoryfca.com
610-860-2075

Tags Business, New Jersey

Business Culture Government Local News Politics Programs & Events

The AACCNJ announces Hon. Tahesha Way, Esq., NJ Lt.-Gov., Secretary of State to make opening remarks at 2024 Black History Month, Black-Tie Gala

TRENTON, N.J. — The African American Chamber of Commerce of New Jersey (AACCNJ) announces that the Honorable Tahesha Way, Esq., NJ Lieutenant Governor and Secretary of State, will make opening remarks at the 14th Annual Circle of Achievement Awards Gala on Feb. 22 at the Venetian in Garfield, N.J.

“We are excited to have the Lieutenant Governor join us for our Black History Month Gala,” said John E. Harmon, Sr., IOM, Founder, President & CEO, AACCNJ.

“We are at a critical juncture for our co-existence in NJ. The Lieutenant Governor’s presence is significant and appreciated as we look forward to advancing a more intentional economic agenda to improve the social economic standing of Black people in NJ. This will be a night of Excellence on full display.”

The AACCNJ 2024 Annual Awards Gala themed “Leading the Way” is the premier Black History Month event in the state of NJ. Each year at the black-tie affair, the AACCNJ recognizes a distinguished group of African Americans that have attained a significant level of accomplishment in business, politics, education, sports and/or entertainment. The event provides the platform, on behalf of the members of the AACCNJ and the over 88,000 Black owned businesses in the state of NJ, to continue to increase the visibility of its members and their businesses.

2024 Honorees:

The Honorable Benjamin Crump, Founder & Principal, Ben Crump Law; will be presented with the Presidential Award of Excellence. Brett J. Hart, President, United Airlines, and Dr. Darcella Patterson Sessomes, Chief, Division of Programs and Reintegration Services, State of New Jersey, Department of Corrections will both receive the Community Service Award. Keith D. Wright, PhD., Director, Business Diversity Operations, Office of Diversity, Equity & Inclusion, Port Authority of NY&NJ will receive the Public Service Award.

The evening will begin with a “Black Carpet Experience” for the attendees, honorees and guests and will also include a Cocktail Reception in the Grand Ballroom and dinner, dancing, and the Awards Ceremony in the Palazzo Ballroom.

The 2024 Gala “Exclusive” Sponsor is Truist. Gala Gold Sponsors include Atlantic Health Center, Consolidated Edison, Horizon Blue Cross Blue Shield of NJ, Milhouse Engineering, PSEG, Provident Bank, United Airlines, Valley National Bank. Silver Sponsors include American Water, Atlantic City Electric, Atlantic Shore Winds, Citizen’s Bank, Davis EIS, JCP&L, Lakeland Bank, NJ Economic Development Authority (NJEDA), PNC and SJI.

More information can be found at www.aaccnj.com https://www.aaccnj.com/gala

About the African American Chamber of Commerce of New Jersey

Culture Education Environment Lifestyle Local News Programs & Events

Lenape Storytelling with Chief Bluejay to commune at D&R Greenway’s Discovery Center at Point Breeze in Bordentown

Post author By Editor
Post date January 23, 2024
No Comments on Lenape Storytelling with Chief Bluejay to commune at D&R Greenway’s Discovery Center at Point Breeze in Bordentown

The public is invited to an afternoon of Lenape Storytelling on Sunday, Jan. 28 from 2 to 4 p.m. at D&R Greenway Land Trust’s Discovery Center at Point Breeze, located at 101 East Park St., Bordentown, N.J.

The public is invited to enjoy an afternoon of storytelling in the tradition of the Lenape, the First People, at D&R Greenway’s Discovery Center at Point Breeze on Sunday, Jan. 28, from 2 p.m. to 4 p.m.

Photo: Visit the Discovery Center at Point Breeze

Photo: Chief Bluejay and Uma Cinnamon in the Peoples Room at the Discovery Center

The Discovery Center was created by D&R Greenway Land Trust in a renovated historic home that belonged to the exiled King of Spain Joseph Napoleon Bonaparte’s gardener in the early 1800s. The house will be open with exhibits about the history, land and people of Point Breeze, including the Lenape and Bonaparte, birds and the Delaware River watershed. Visitors learn about the Three Sisters garden, indigenous and heritage crops that are grown in the Historic Garden at Point Breeze.

“Wintertime is when indigenous peoples gather to tell stories” says Barbara Michalski, known as Chief Bluejay. Of Lenape descent, she is Chief, Keeper of Culture, Storyteller and Public Speaker for the Lenape Nation of Pennsylvania. She is a talented storyteller who shares the traditions of the Lenape to remind people that “we are still here.” Bluejay provided advice to D&R Greenway in development of the Peoples Room inside the Discovery Center at Point Breeze. There, visitors will learn about Lenape language and read stories about land and water stewardship. Chief Bluejay’s intention is “to stress how we should take care of Mother Earth.”

A landmark positioned in front of the Historic Garden at the Discovery Center at Point Breeze is a life-size sculpture of an Atlantic Sturgeon. These huge creatures, that can grow up to 14 feet in length, were once abundant in the Delaware River but were taken to the brink of extinction due to loss of habitat. They depend on clean water to spawn in the Delaware River. Native Americans fished these creatures for food and used the remains as fertilizer for agricultural crops. Visitors to the open house will have an opportunity to color Sturgeon cards provided by the Delaware Riverkeeper. The cards will be hung on our tree inside the Crown Jewels Gallery to transition the holiday tree to a “Sturgeon Family Tree” and share wishes for protecting the Atlantic Sturgeon and the Delaware River.

In the Natural World Room visitors will find wood carvings for sale by artist Jane “Walkingstick” Roop, of Lenape descent. Walking Sticks, Spirit Sticks, and various carvings are available for prices ranging from $35 – $225, with a portion of the sales supporting programs at the D&R Greenway’s Discovery Center at Point Breeze.

Photo: Lenape wood carvings available for purchase at the Discovery Center

“This special opportunity celebrates a community of people and special features of the Delaware River watershed that are truly treasures,” says Linda Mead, D&R Greenway’s President & CEO. “Working in partnership with Chief Bluejay, Jane Walkingstick and other members of the Lenape Nation has been an honor for me and carries out D&R Greenway’s mission to protect land and water and inspire a conservation ethic.”

Admission to the Storytelling program and the Discovery Center at Point Breeze is free. A suggested donation of $10 provides the donor with a souvenir magnet or bag, and supports programs and exhibits.

The afternoon program is an open house format. Visitors are invited to join during the open hours for ongoing stories and activities. The Discovery Center’s exhibits on Native Americans, King Joseph Napoleon Bonaparte, gardens, birds and the Delaware River watershed will be open to view. Registration suggested at info@drgreenway.org or call 609-924-4646.

####

About D&R Greenway Land Trust: D&R Greenway Land Trust is an accredited nonprofit that has reached a new milestone of over 22,000 acres of land preserved throughout central New Jersey since 1989. By protecting land in perpetuity and creating public trails, it gives everyone the opportunity to enjoy the great outdoors. The land trust’s preserved farms and community gardens provide local organic food for residents of the region—including those most in need. Through strategic land conservation and stewardship, D&R Greenway combats climate change, protects birds and wildlife, and ensures clean drinking water for future generations. D&R Greenway’s mission is centered on connecting land with people from all walks of life. www.drgreenway.org; info@drgreenway.org. Follow us on Facebook and Instagram.

Education Healthcare Lifestyle Local News News Now! Programs & Events Science

Bristol Myers Squibb Data at ASCO GU 2024 showcase transformative research in genitourinary cancer treatment

Post author By Michelle Dryden
Post date January 17, 2024
No Comments on Bristol Myers Squibb Data at ASCO GU 2024 showcase transformative research in genitourinary cancer treatment

First presentation of results from Phase 3 CheckMate -67T trial with subcutaneous formulation of Opdivo (nivolumab and hyaluronidase) to be shared in a late-breaking oral presentation

Four-year data from CheckMate -9ER and unprecedented eight-year data from CheckMate -214 will confirm durable outcomes with Opdivo-based combinations for patients with advanced renal cell carcinoma

First disclosure of clinical outcomes from Phase 1 trial with BMS-986365 (CC-94676), the company’s first androgen receptor ligand-directed degrader in solid tumors from its targeted protein degradation platform, in metastatic castration-resistant prostate cancer

PRINCETON, N.J. — (BUSINESS WIRE) — $BMY #ASCO—Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data at the American Society of Clinical Oncology 2024 Genitourinary Cancers Symposium (ASCO GU) to be held from Jan. 25 to 27 in San Francisco, Calif., highlighting the company’s progress in making long-term survival outcomes a possibility for more patients with genitourinary cancers, as well as showcasing potential new options and therapeutic platforms that may transform treatment paradigms across tumor types.

Data from 14 company-sponsored studies, investigator-sponsored studies and collaborations will be presented at the meeting.

The first presentation of data from the CheckMate -67T study will highlight the potential of a subcutaneous formulation of nivolumab co-formulated with Halozyme’s proprietary recombinant human hyaluronidase (rHuPH20) in advanced or metastatic clear cell renal cell carcinoma (RCC). Research to be shared will also add to the evidence supporting the use of Opdivo (nivolumab)-based combinations in patients with advanced RCC, including four-year follow-up data from the CheckMate -9ER trial and eight-year results from the CheckMate -214 trial. In addition, data will be presented on an investigational androgen receptor (AR) ligand-directed degrader (LDD; BMS-986365) in metastatic castration-resistant prostate cancer (mCRPC), providing validation for the targeted protein degradation platform in solid tumors and representing one of the company’s next waves of potential registrational assets.

“We are excited to present our research at ASCO GU 2024, which will demonstrate not only our long-standing leadership in oncology with our work in immunotherapy, but also our commitment to developing new assets and approaches to treating cancer from our differentiated research platforms such as targeted protein degradation in an effort to provide patients with better, long-term outcomes,” said Samit Hirawat, M.D., executive vice president and chief medical officer, Drug Development, Bristol Myers Squibb.

“These results simultaneously showcase the ongoing success of Opdivo-based combinations in metastatic disease and our contributions to the future of cancer treatment and research. We are especially eager to share data for the first time showing the potential of our subcutaneous formulation of a proven agent, and a new mechanism of action in a difficult-to-treat tumor type – both of which could have a tremendous impact on existing standards of care and the patient experience.”

Key data being presented by Bristol Myers Squibb at ASCO GU 2024 include:

First disclosure of pharmacokinetics, efficacy and safety results from the Phase 3 CheckMate -67T trial with subcutaneous nivolumab (nivolumab and hyaluronidase) being presented in a late-breaking oral session. This marks the first presentation of data evaluating subcutaneous nivolumab compared to its intravenous formulation.
Eight-year data from the Phase 3 CheckMate -214 study with Opdivo plus Yervoy (ipilimumab) showing ongoing survival and response benefits over sunitinib among intermediate- and poor-risk patients with advanced RCC, as well as among all randomized patients. These data represent the longest survival benefit vs. sunitinib reported in patients with previously untreated advanced or metastatic RCC.
Four-year follow-up data from the Phase 3 CheckMate -9ER trial evaluating Opdivo in combination with Exelixis’ CABOMETYX (cabozantinib). These data demonstrate meaningful, long-term efficacy benefits seen with the combination therapy over sunitinib and reinforce it as a standard of care for previously untreated advanced RCC.
First presentation of clinical outcomes from the company’s targeted protein degradation platform in solid tumors with Phase 1 data from BMS-986365 (CC-94676), an oral drug selectively targeting AR. BMS-986365 induces effective and durable suppression of AR signaling, overcomes resistance to existing AR pathway inhibitors (ARPI) therapies and shows promising clinical activity in heavily pre-treated patients with mCRPC across wildtype, amplified and mutant AR status, highlighting this asset as the potential best-in-class AR-ligand directed degrader that may help overcome resistance to standard of care ARPIs in patients with mCRPC, a difficult-to-treat tumor type.

Summary of Presentations:

Abstract Title	Author	Presentation Type/#	Session Title	Session Date/Time (ET)
*Prostate Cancer*
First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).	Dana Rathkopf	Poster Abstract #134 Poster Bd. #F5	Poster Session A: Prostate Cancer	Thursday, January 25 2:30 PM – 4:00 PM
*Renal Cell Carcinoma*
Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Pharmacokinetics (PK), efficacy, and safety results from CheckMate 67T.	Saby George	Oral Abstract #LBA360	Oral Abstract Session C: Renal Cell Cancer	Saturday, January 27 11:10 AM – 12:45 PM
Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Results from 55-month follow-up of the CheckMate 9ER trial.	Maria Teresa Bourlon	Rapid Oral Abstract #362	Rapid Oral Abstract Session C: Renal Cell, Adrenal, and Testicular Cancers	Saturday, January 27 4:00 PM – 5:15 PM
Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial.	Nizar Tannir	Rapid Oral Abstract #363	Rapid Oral Abstract Session C: Renal Cell, Adrenal, and Testicular Cancers	Saturday, January 27 4:00 PM – 5:15 PM
Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: Results from Part B of the randomized, phase 3 CheckMate 914 trial.	Robert Motzer	Oral Abstract #LBA358	Oral Abstract Session C: Renal Cell Cancer	Saturday, January 27 11:10 AM – 12:45 PM
Treatment patterns and costs among patients with metastatic renal cell carcinoma (mRCC) in the United States: A real-world study using integrated claims and clinical data.	Daniel Geynisman	Poster Abstract #398 Poster Bd. #F22	Poster Session C: Renal Cell Cancer; Adrenal, Penile, and Testicular Cancers	Saturday, January 27 10:00 AM – 11:00 AM
*Urothelial Carcinoma*
Estimating the impact of adjuvant treatment with nivolumab on long-term survivorship rates compared with surveillance: Analyses of disease-free survival (DFS) from the phase 3 CheckMate-274 trial.	Daniel Geynisman	Oral Abstract #528	Role of Immunotherapy in Advanced Urothelial Carcinoma: Sequencing, Pairing, Rechallenging	Friday, January 26 5:30 PM – 6:45 PM
Characteristics of patients (pts) with muscle-invasive urothelial carcinoma (MIUC) who received adjuvant nivolumab (NIVO) or adjuvant platinum-based chemotherapy (CHEMO) in the real-world (RW) setting.	Alex Chehrazi-Raffle	Poster Abstract #565 Poster Bd. #E14	Poster Session B: Urothelial Carcinoma	Friday, January 26 2:30 PM – 4:00 PM

All abstracts except late-breaking abstracts will be available on ASCO’s digital program at 5:00 PM Eastern Time (ET) on January 22, 2024. All late-breaking abstracts will be available on ASCO’s digital program at 10:00 AM ET on their day of presentation at the meeting.

Bristol Myers Squibb: Creating a Better Future for People with Cancer

Bristol Myers Squibb is inspired by a single vision — transforming patients’ lives through science. The goal of the company’s cancer research is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility. Building on a legacy across a broad range of cancers that have changed survival expectations for many, Bristol Myers Squibb researchers are exploring new frontiers in personalized medicine and, through innovative digital platforms, are turning data into insights that sharpen their focus. Deep understanding of causal human biology, cutting-edge capabilities and differentiated research platforms uniquely position the company to approach cancer from every angle.

Cancer can have a relentless grasp on many parts of a patient’s life, and Bristol Myers Squibb is committed to taking actions to address all aspects of care, from diagnosis to survivorship. As a leader in cancer care, Bristol Myers Squibb is working to empower all people with cancer to have a better future.

About Opdivo

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Opdivo’s leading global development program is based on Bristol Myers Squibb’s scientific expertise in the field of Immuno-Oncology, and includes a broad range of clinical trials across all phases, including Phase 3, in a variety of tumor types. To date, the Opdivo clinical development program has treated more than 35,000 patients. The Opdivo trials have contributed to gaining a deeper understanding of the potential role of biomarkers in patient care, particularly regarding how patients may benefit from Opdivo across the continuum of PD-L1 expression.

In July 2014, Opdivo was the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world. Opdivo is currently approved in more than 65 countries, including the United States, the European Union, Japan and China. In September 2015, the Company’s Opdivo and Yervoy combination regimen was the first Immuno-Oncology to receive regulatory approval for the treatment of metastatic melanoma and is currently approved in more than 50 countries, including the United States and the European Union.

About Yervoy

Yervoy is a recombinant, human monoclonal antibody that binds to the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4). CTLA-4 is a negative regulator of T-cell activity. Yervoy binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, CD80/CD86. Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation, including the activation and proliferation of tumor infiltrating T-effector cells. Inhibition of CTLA-4 signaling can also reduce T-regulatory cell function, which may contribute to a general increase in T-cell responsiveness, including the anti-tumor immune response. On March 25, 2011, the U.S. Food and Drug Administration (FDA) approved Yervoy 3 mg/kg monotherapy for patients with unresectable or metastatic melanoma. Yervoy is approved for unresectable or metastatic melanoma in more than 50 countries. There is a broad, ongoing development program in place for Yervoy spanning multiple tumor types.

INDICATIONS

OPDIVO® (nivolumab), as a single agent, is indicated for the treatment of adult and pediatric patients 12 years of age and older with unresectable or metastatic melanoma.

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the treatment of adult and pediatric patients 12 years of age and older with unresectable or metastatic melanoma.

OPDIVO® is indicated for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma.

OPDIVO® (nivolumab), in combination with platinum-doublet chemotherapy, is indicated as neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer (NSCLC).

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab) and 2 cycles of platinum-doublet chemotherapy, is indicated for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.

OPDIVO® (nivolumab) is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO.

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma (MPM).

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the first-line treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma (RCC).

OPDIVO® (nivolumab), in combination with cabozantinib, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).

OPDIVO® (nivolumab) is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.

OPDIVO® (nivolumab) is indicated for the treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin or after 3 or more lines of systemic therapy that includes autologous HSCT. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

OPDIVO® (nivolumab) is indicated for the treatment of adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy.

OPDIVO® (nivolumab) is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

OPDIVO® (nivolumab), as a single agent, is indicated for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC.

OPDIVO® (nivolumab), as a single agent, is indicated for the treatment of adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the treatment of adults and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

OPDIVO® (nivolumab) is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.

OPDIVO® (nivolumab) is indicated for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in adult patients who have received neoadjuvant chemoradiotherapy (CRT).

OPDIVO® (nivolumab), in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC).

OPDIVO® (nivolumab), in combination with YERVOY® (ipilimumab), is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC).

OPDIVO® (nivolumab), in combination with fluoropyrimidine- and platinum- containing chemotherapy, is indicated for the treatment of adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.

IMPORTANT SAFETY INFORMATION

Severe and Fatal Immune-Mediated Adverse Reactions

Immune-mediated adverse reactions listed herein may not include all possible severe and fatal immune- mediated adverse reactions.

Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue. While immune-mediated adverse reactions usually manifest during treatment, they can also occur after discontinuation of OPDIVO or YERVOY. Early identification and management are essential to ensure safe use of OPDIVO and YERVOY. Monitor for signs and symptoms that may be clinical manifestations of underlying immune-mediated adverse reactions. Evaluate clinical chemistries including liver enzymes, creatinine, adrenocorticotropic hormone (ACTH) level, and thyroid function at baseline and periodically during treatment with OPDIVO and before each dose of YERVOY. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.

Withhold or permanently discontinue OPDIVO and YERVOY depending on severity (please see section 2 Dosage and Administration in the accompanying Full Prescribing Information). In general, if OPDIVO or YERVOY interruption or discontinuation is required, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroid therapy. Toxicity management guidelines for adverse reactions that do not necessarily require systemic steroids (e.g., endocrinopathies and dermatologic reactions) are discussed below.

Immune-Mediated Pneumonitis

OPDIVO and YERVOY can cause immune-mediated pneumonitis. The incidence of pneumonitis is higher in patients who have received prior thoracic radiation. In patients receiving OPDIVO monotherapy, immune- mediated pneumonitis occurred in 3.1% (61/1994) of patients, including Grade 4 (<0.1%), Grade 3 (0.9%), and Grade 2 (2.1%). In patients receiving OPDIVO 1 mg/kg with YERVOY 3 mg/kg every 3 weeks, immune- mediated pneumonitis occurred in 7% (31/456) of patients, including Grade 4 (0.2%), Grade 3 (2.0%), and Grade 2 (4.4%). In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, immune- mediated pneumonitis occurred in 3.9% (26/666) of patients, including Grade 3 (1.4%) and Grade 2 (2.6%). In NSCLC patients receiving OPDIVO 3 mg/kg every 2 weeks with YERVOY 1 mg/kg every 6 weeks, immune- mediated pneumonitis occurred in 9% (50/576) of patients, including Grade 4 (0.5%), Grade 3 (3.5%), and Grade 2 (4.0%). Four patients (0.7%) died due to pneumonitis.

In Checkmate 205 and 039, pneumonitis, including interstitial lung disease, occurred in 6.0% (16/266) of patients receiving OPDIVO. Immune-mediated pneumonitis occurred in 4.9% (13/266) of patients receiving OPDIVO, including Grade 3 (n=1) and Grade 2 (n=12).

Immune-Mediated Colitis

OPDIVO and YERVOY can cause immune-mediated colitis, which may be fatal. A common symptom included in the definition of colitis was diarrhea. Cytomegalovirus (CMV) infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis. In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies. In patients receiving OPDIVO monotherapy, immune-mediated colitis occurred in 2.9% (58/1994) of patients, including Grade 3 (1.7%) and Grade 2 (1%).

In patients receiving OPDIVO 1 mg/kg with YERVOY 3 mg/kg every 3 weeks, immune-mediated colitis occurred in 25% (115/456) of patients, including Grade 4 (0.4%), Grade 3 (14%) and Grade 2 (8%). In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, immune-mediated colitis occurred in 9% (60/666) of patients, including Grade 3 (4.4%) and Grade 2 (3.7%).

Immune-Mediated Hepatitis and Hepatotoxicity

OPDIVO and YERVOY can cause immune-mediated hepatitis. In patients receiving OPDIVO monotherapy, immune-mediated hepatitis occurred in 1.8% (35/1994) of patients, including Grade 4 (0.2%), Grade 3 (1.3%), and Grade 2 (0.4%).

In patients receiving OPDIVO 1 mg/kg with YERVOY 3 mg/kg every 3 weeks, immune-mediated hepatitis occurred in 15% (70/456) of patients, including Grade 4 (2.4%), Grade 3 (11%), and Grade 2 (1.8%). In patients receiving OPDIVO 3 mg/kg with YERVOY 1 mg/kg every 3 weeks, immune-mediated hepatitis occurred in 7% (48/666) of patients, including Grade 4 (1.2%), Grade 3 (4.9%), and Grade 2 (0.4%).

OPDIVO in combination with cabozantinib can cause hepatic toxicity with higher frequencies of Grade 3 and 4 ALT and AST elevations compared to OPDIVO alone. Consider more frequent monitoring of liver enzymes as compared to when the drugs are administered as single agents. In patients receiving OPDIVO and cabozantinib, Grades 3 and 4 increased ALT or AST were seen in 11% of patients.

Immune-Mediated Endocrinopathies

OPDIVO and YERVOY can cause primary or secondary adrenal insufficiency, immune-mediated hypophysitis, immune-mediated thyroid disorders, and Type 1 diabetes mellitus, which can present with diabetic ketoacidosis.

Contacts

Bristol Myers Squibb

Media Inquiries:
media@bms.com

Investors:
investor.relations@bms.com

Read full story here

Tags Business, New Jersey